Navigation Links
Shaji Procida Appointed Vice President and Chief Financial Officer of Eisai Inc.
Date:6/22/2012

WOODCLIFF LAKE, N.J., June 22, 2012 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Shaji Procida to the position of Vice President and Chief Financial Officer. Previously, Ms. Procida held the position of Vice President of Finance. In her elevated role, she will have oversight and responsibility for all of Eisai's financial operations in the United States. In addition, she will continue to serve as a member of the company's Executive Committee. 

(Photo:  http://photos.prnewswire.com/prnh/20120622/NY29079 )

(Logo:  http://photos.prnewswire.com/prnh/20120413/MM87168LOGO )

Ms. Procida has had a long and successful career at Eisai. She joined the company in 1998 as Manager of Financial Consolidations and Reporting. Over the years, she has held positions of increasing responsibility within finance and accounting. In 2005, Ms. Procida was appointed into the key leadership role of Controller, where she led the accounting, financial reporting, budgeting and consolidation functions. In 2010, she was promoted to Vice President of Finance.

"Shaji is a consummate professional who has been a key advisor within our organization," said Lonnel Coats, President and CEO of Eisai Inc. "Her expertise and business leadership will continue to ensure our company's financial well-being as well as support our ongoing efforts to achieve our human health care mission of helping to improve the lives of patients and their families."

Ms. Procida holds a Bachelor of Business Administration in accounting from Pace University. She also is a member of the Financial Executive Institute and the Healthcare Businesswomen's Association (HBA). In 2006, Ms. Procida was recognized as a Rising Star by the HBA at its annual Woman of the Year event. 

Eisai Inc.

Eisai Inc. was established in 1995 and began marketing its first product in the United States in 1997. Since that time, Eisai Inc. has rapidly grown to become a fully integrated pharmaceutical business. Eisai's key areas of commercial focus are neurology and oncology. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. 

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as manufacturing facilities in Maryland and North Carolina. The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com/US.

Eisai Co., Ltd.

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system.


'/>"/>
SOURCE Eisai Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Neal K. Long appointed as Chief Executive Officer at Cardiac Science
2. Dr. Paul Karila Appointed Head of Discovery Services at Cellectricon AB
3. Israel Makov Appointed Chairman of Sun Pharma Board
4. New Executive Vice President Commercial Appointed
5. Herb Baer Appointed President of Polar USA
6. A New Audio Interview With Ronald Adams President Of Medical Alarm Concepts Holding, Inc., Is Now At SmallCapVoice.com
7. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
8. Ted Pacha Joins Pinnaclife as President of its Healthcare Distribution Division
9. David F. Harty Joins Systech International as Vice President
10. AMRI Announces President for AMRI Europe
11. GenVec Appoints Cynthia Collins as President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... March 29, 2017 Varian Medical Systems (NYSE: ... for the second quarter of fiscal year 2017 following the ... news release will be followed by a teleconference available to ... and a link to the conference call webcast will be ... access the teleconference call and replay: ...
(Date:3/29/2017)... AMSTERDAM , March 29, 2017   ... global leader in health technology, and PathAI, a ... are collaborating with the aim to develop solutions ... diagnosis of cancer and other diseases. The partnership ... pathology, enabling this form of artificial intelligence to ...
(Date:3/29/2017)... AVIV, Israel , March 29, 2017 ... agreement in which Exeltis will obtain exclusive marketing rights for Neurim,s ... ... an age-appropriate drug targeted to treat sleep disorders in children with ... be the first sleep medication approved for children. The ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... HealthCareMandA.com will host an important webinar ... at 1:00 PM ET. A recording of the webinar will also be made available ... Home health and hospice companies are still popular targets for healthcare investors. This highly ...
(Date:3/29/2017)... North Hollywood, CA (PRWEB) , ... March 29, 2017 , ... ... and Northridge , is now offering laser dental treatments. Dental lasers are safe ... treatments. Laser dentistry expands patients’ options and can improve the overall quality of care. ...
(Date:3/29/2017)... , ... March 29, 2017 , ... The Wharton School ... and Julie Taffet Moelis, W’81, have made a $10 million gift to establish the ... opportunity that will provide a pathway to a Wharton MBA for highly-qualified Penn undergraduates ...
(Date:3/28/2017)... ... March 28, 2017 , ... A recent Bellwether Education ... quality, the field must first improve teacher preparation program design. It then asserts ... and that decades of input- and outcome-based research has failed to improve teacher ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... first technology to directly address the resolution to globally reduce the harmful use ... patented compound of FDA and TTB approved ingredients that when infused into alcohol, ...
Breaking Medicine News(10 mins):